In this phase 1/2 trial, AVT001 did not result in dose-limiting adverse events. Potential signals of efficacy observed here warrant further evaluation in a fully powered trial. (Funded by Avotres Inc. and the Division of Diabetes, Endocrinology, and Metabolic Diseases; ClinicalTrials.gov number, NCT03895996.).
Keyphrases
- type diabetes
- dendritic cells
- glycemic control
- cardiovascular disease
- regulatory t cells
- study protocol
- cell therapy
- phase iii
- clinical trial
- bone marrow
- phase ii
- insulin resistance
- immune response
- platelet rich plasma
- randomized controlled trial
- human health
- risk assessment
- metabolic syndrome
- skeletal muscle
- smoking cessation
- replacement therapy